Cargando…
Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility?
INTRODUCTION: As the Coronavirus Disease 2019 (COVID-19) pandemic unfolds around the world; answers related to the antibody response against the virus are necessary to develop treatment and prophylactic strategies. We attempted to understand part of the immune response of convalescent plasma donatio...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566374/ https://www.ncbi.nlm.nih.gov/pubmed/34751255 http://dx.doi.org/10.1016/j.htct.2021.07.008 |
_version_ | 1784593997630537728 |
---|---|
author | Prudente, Tiago Paiva Castro, Renato Gomes Candido, Marcos Antonio Rodrigues, Roberta Luiza de Souza, Layane Marques Roberti, Maria do Rosario Ferraz |
author_facet | Prudente, Tiago Paiva Castro, Renato Gomes Candido, Marcos Antonio Rodrigues, Roberta Luiza de Souza, Layane Marques Roberti, Maria do Rosario Ferraz |
author_sort | Prudente, Tiago Paiva |
collection | PubMed |
description | INTRODUCTION: As the Coronavirus Disease 2019 (COVID-19) pandemic unfolds around the world; answers related to the antibody response against the virus are necessary to develop treatment and prophylactic strategies. We attempted to understand part of the immune response of convalescent plasma donation candidates. METHOD: We carried out a cross-sectional, observational, non-intervention study, testing 102 convalescent plasma donation candidates for antibodies against the virus, relating these data to the time interval between symptom onset and sample collection, age, disease severity, and gender. RESULTS: In our sample, the individuals who developed a greater antibody response were the ones who had a longer time interval between symptom onset and sample collection, the ones who had been hospitalized and the subjects above 35 years old. Moreover, 17 individuals did not present any reactive antibodies. CONCLUSION: These results are important in that they raise questions about the role of the humoral response against the virus, as some individuals do not develop antibodies to fight it. In addition, they help develop recruitment strategies for convalescent plasma donors, who should be asymptomatic for at least 21 days and are possibly more likely to have reactive antibodies after 35 days without symptoms. |
format | Online Article Text |
id | pubmed-8566374 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Sociedade Brasileira de Hematologia e Hemoterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-85663742021-11-04 Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility? Prudente, Tiago Paiva Castro, Renato Gomes Candido, Marcos Antonio Rodrigues, Roberta Luiza de Souza, Layane Marques Roberti, Maria do Rosario Ferraz Hematol Transfus Cell Ther Original Article INTRODUCTION: As the Coronavirus Disease 2019 (COVID-19) pandemic unfolds around the world; answers related to the antibody response against the virus are necessary to develop treatment and prophylactic strategies. We attempted to understand part of the immune response of convalescent plasma donation candidates. METHOD: We carried out a cross-sectional, observational, non-intervention study, testing 102 convalescent plasma donation candidates for antibodies against the virus, relating these data to the time interval between symptom onset and sample collection, age, disease severity, and gender. RESULTS: In our sample, the individuals who developed a greater antibody response were the ones who had a longer time interval between symptom onset and sample collection, the ones who had been hospitalized and the subjects above 35 years old. Moreover, 17 individuals did not present any reactive antibodies. CONCLUSION: These results are important in that they raise questions about the role of the humoral response against the virus, as some individuals do not develop antibodies to fight it. In addition, they help develop recruitment strategies for convalescent plasma donors, who should be asymptomatic for at least 21 days and are possibly more likely to have reactive antibodies after 35 days without symptoms. Sociedade Brasileira de Hematologia e Hemoterapia 2022 2021-11-04 /pmc/articles/PMC8566374/ /pubmed/34751255 http://dx.doi.org/10.1016/j.htct.2021.07.008 Text en © 2021 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Prudente, Tiago Paiva Castro, Renato Gomes Candido, Marcos Antonio Rodrigues, Roberta Luiza de Souza, Layane Marques Roberti, Maria do Rosario Ferraz Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility? |
title | Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility? |
title_full | Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility? |
title_fullStr | Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility? |
title_full_unstemmed | Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility? |
title_short | Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility? |
title_sort | antibody response against sars-cov-2 in convalescent plasma donors: can we predict subjects’ eligibility? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566374/ https://www.ncbi.nlm.nih.gov/pubmed/34751255 http://dx.doi.org/10.1016/j.htct.2021.07.008 |
work_keys_str_mv | AT prudentetiagopaiva antibodyresponseagainstsarscov2inconvalescentplasmadonorscanwepredictsubjectseligibility AT castrorenatogomes antibodyresponseagainstsarscov2inconvalescentplasmadonorscanwepredictsubjectseligibility AT candidomarcosantonio antibodyresponseagainstsarscov2inconvalescentplasmadonorscanwepredictsubjectseligibility AT rodriguesrobertaluiza antibodyresponseagainstsarscov2inconvalescentplasmadonorscanwepredictsubjectseligibility AT desouzalayanemarques antibodyresponseagainstsarscov2inconvalescentplasmadonorscanwepredictsubjectseligibility AT robertimariadorosarioferraz antibodyresponseagainstsarscov2inconvalescentplasmadonorscanwepredictsubjectseligibility |